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Occidiofungin is a natural antifungal compound produced by Burkholderia contaminans MS14.
Prior work has been shown occidiofungin to be effective against Candida albicans in its nonpathogenic yeast form. However, C. albicans is an opportunistic pathogen that requires a
morphogenic switch to a filamentous form to cause disease. As previous work focusing on the
non-pathogenic form has shown distinct biochemical and morphological changes with
occidiofungin exposure, I hypothesis that the filamentous form of this fungi will also undergo
identifiable changes that can be characterized. To this end, cells induced to undergo
morphological switching in the presence of occidiofungin were analyzed by standard
microbiological methods. Data showed that a lethal dose of the antifungal prevented hyphae
formation while a sublethal dose slowed filament growth without obvious alterations in cell wall
organization. These data adds to our understanding of occidiofungin’s potential as an antifungal
compound to combat the pathogenic form of Candida albicans.
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CHAPTER I
INTRODUCTION
Opportunistic pathogens are a large group of disease-causing organisms that most
individuals encounter on a daily basis. These microorganisms can coexist with human
populations without posing a danger to a healthy individual. However, if placed into the right set
of circumstances such as altered temperatures, changes in resource availability, abnormal
location in the body, or other situations, they can become pathogens (Kabir, Hussain, & Ahmad,
2012). Once these microbes have made the change to a pathogenic state, a wide range of
potential life-threatening diseases can arise. These diseases can be especially dangerous for those
individuals who are immunocompromised, surgical patients, transplant recipients, or long-term
hospitalized individuals. This presents a unique problem for the medical community as some of
these opportunistic pathogens are key members of the human microbiome. This makes the
practice of limiting contact with these pathogens as a means of prevention impossible. This,
coupled with the fact that many of these pathogens have evolved resistance to the drugs
commonly used to eliminate them, makes the identification of new treatment protocols an
imperative for the research community.
Opportunistic pathogens can be bacterial in origin (i.e. prokaryotic) or eukaryotic
organisms and are found across a range of different genera and species. Some opportunistic
pathogens are harbored in the natural environment and rarely cause infection in healthy
individuals. Some common commensal bacteria such as Streptococcus pneumoniae and
1

Staphylococcus aureus can become disease causing agents under the right circumstances
(Brown, Cornforth, & Mideo, 2012). S. aureus is capable of causing potentially fatal disease, yet
many health individuals are colonized in anterior nostrils. P. aeruginosa is a known
environmental opportunistic pathogen that can cause dangerous infections in
immunocompromised patients (Sadikot, Blackwell, Christman, & Prince, 2005). Several of the
eukaryotic pathogens are from the Fungi kingdom with very distinct characteristics. Fungi are
ubiquitous to many environments and are contacted daily. The Center for Disease Control (CDC)
estimates that there are about 300 different fungi that can cause disease including Aspergillus,
Cryptococcus, Histoplasma, and various Candida species (Moore, Robson, & Trinci, 2011).
Candida albicans is the most important opportunistic pathogen of the human gut flora. C.
albicans exists in two different developmental morphologies: a yeast form and a hyphae form
(Arkowitz & Bassilana, 2011). The yeast form exists as a common commensal microorganism of
the human microbiome. In contrast, the hyphae form is known to be associated with virulence
and can cause a range of diseases (Pukkila-Worley, Peleg, Tampakakis, & Mylonakis, 2009). For
example, if C. albicans enters into the blood stream and leads to systemic spreading, this is
referred to as invasive candidiasis. For immunocompromised patients this can be fatal (PukkilaWorley et al., 2009). The exact mechanism driving virulence in C. albicans is not fully
understood, but specialized proteins produced by cells in their hyphae form are thought to cause
some disease symptoms. A lowered state of immune response can also result in more severe
disease progression making this organism of medical relevance within many areas of the health
care system.
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While prevention of Candidiasis by limiting exposure is important, the ubiquitous nature
of this organism makes complete exclusion impossible. Thus, treatment with various antifungals
is a first line of defense for medical professionals. These antifungal compounds work best if their
targets are unique or conserved to fungi. Antifungals of the azole family target ergosterol which
is a key component of the fungal cell wall. Ergosterol is similar to cholesterol in mammalian
cells and functions to stabilize the plasma membrane (Gow, Latge, & Munro, 2017). The cell
wall is another key difference between fungi and mammalian cells and is also the target of
antifungal drugs. The fungal cell wall is composed of proteins, chitin, and glycans and functions
to protect the cell from osmotic and structural damage. Antifungals that target a fungal enzyme
involved in generating the glycans present in the cell wall include those in the echinocandin
family (Hawser, Francolini, & Islam, 1996). Inhibiting an enzyme required for cell wall
synthesis weakens the cell wall which disrupts the cell’s ability to compensate for osmotic
stressors, ultimately resulting in cell death. Targeting unique properties of fungal cells is
important when trying to identify/develop new antifungal treatments. The less unique the
treatment target, the more chance for side effects from the treatment. Resistance to antifungals
must always be a concern in the health care industry. Resistance mechanisms can vary based on
the drug and organism but often involve the accumulation of mutagenic changes that allows the
organism to survive higher than therapeutic doses of the drug. For example, resistance to
echinocandins arise from the acquisition of amino acid mutations in a region of the target
enzyme which prevents antifungal binding (Spampinato & Leonardi, 2013). The CDC has been
tracking the emergence of multidrug resistant strains of C. albicans which is a growing concern
as no new antifungal treatments have been developed for clinical treatment in many years
(Cleveland et al., 2015).
3

The danger of resistance to antifungals has broader implications than just the health care
industry. The agricultural industry must also contend with a wide range of microbial pathogens
that can devastate crops. Nearly every food crop can be affected by fungal pathogens which
could compromise food security. Nearly 18% of crop loss is caused by microbial agents and 70%
of these are fungal in nature (Savary, Ficke, Aubertot, & Hollier, 2012). There are far more
pathogenic fungal diseases than any other form of pathogens that impact crops. Wheat is one of
the largest crops in the U.S. and accounts for near 15 billion dollars in annual revenues. A major
fungal pathogen of wheat is Rust disease which is caused by Puccinia graminis. Rust disease
associated with grains such as wheat has been estimated to cause up to 5 billion dollars in losses
due to reduced crop yields (Savary et al., 2012). With increasing demand for sustainable food
crops in developing countries, and the growing trend in the U.S. of locally sourced foods, the
development of new methods to protect crops from fungal pathogens is an important focus for
the agriculture industry.
In addition to fungi negatively impacting agriculture through its impact on plants,
pathogenic fungi have also been linked to honey bees. As of 2006, a rapid loss of bee colonies
began to occur in the United States which endangers both honey production and crop agriculture
(Bromenshenk et al., 2010). While our understanding of the cause of colony collapses is not
complete, fungal infection is one of the current possible causes for the decline in bee populations
(Ptaszynska, Borsuk, Anusiewicz, & Mulenko, 2012). Likewise, wildlife populations are also
damaged by fungal pathogens. In recent years, a disorder called “white-nose bat syndrome”
(WNS) has decimated bat populations across the eastern seaboard. The cause of WNS is a fungal
pathogen Pseudogymnoascus destructans which was likely introduced from Europe and spread
4

quickly through populations (Trivedi et al., 2017). Bats are also an important species for U.S.
agriculture because of their role in natural pest control. Conservative estimates place the worth of
this pest control at $3.7 billion dollars annually (Boyles, Cryan, McCracken, & Kunz, 2011).
Bats may also have a role in human health as they control population numbers of mosquito, a
pest that can harbor human pathogens.
Research has identified several new compounds to treat fungal infections. One of these
new compounds was discovered at Mississippi State University and is called occidiofungin (Lu
et al., 2009). This compound was found to be produced by a soil bacterium that associates with
the roots of plants. Occidiofungin has a broad range of antifungal activities and is effective
against both plant and animal fungal pathogens. Interestingly, occidiofungin has antifungal
activity against fungi that have been shown to be resistant to current antifungal agents which
makes this compound a promising agent for further investigations (Lu et al., 2009).
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CHAPTER II
BACKGROUND
C. albicans as model fungal pathogen
C. albicans is a model pathogenic organism for the analysis of novel antifungal
compounds in part because of the human health relevance of this pathogen. Differences in
Candida albicans and the more commonly used budding yeast, Saccharomyces cerevisiae, are
observed (Karathia, Vilaprinyo, Sorribas, & Alves, 2011). S. cerevisiae can be maintained as
either a haploid or a diploid, are easily grown and maintained in a laboratory setting, have well
characterized genetics, an annotated genome, and have commercially available collections of
deletion and overexpression strains that makes genetic screening relatively routine. In contrast,
C. albicans is an obligate diploid cell making genetic alteration more difficult and time
consuming (Kabir et al., 2012). Often both fungal species are used when addressing questions
within the antifungal field.
C. albicans is a well-studied eukaryotic fungus that is a commensal microorganism of
the human gut flora (Kabir et al., 2012). However, when allowed to proliferate in areas of the
body that are outside of its normal environment or in individuals who are in an
immunocompromised state, growth of this organism can give rise to C. albicans becoming a
disease-causing agent. C. albicans is a polymorphic yeast as it can acquire several morphologies
associated with the cell’s life cycle (Arkowitz & Bassilana, 2011). Laboratory cultures of this
organism are commonly maintained in an oval shaped “yeast’ form which reproduces by asexual
6

budding. This yeast form is associated with the commensal colonization of the gut flora and is
typically regarded as non-pathogenic. In contrast, under environmental stressors such as elevated
temperature, elevated pH, elevated CO2/reduced O2 levels, or limited nutrient availability, the
yeast cell will undergo a morphological switch to a hyphae form (Whiteway & Bachewich,
2007). This form is marked by a long filamentous extension from the cell body. This form of C.
albicans will undergo sexual reproduction with the diploid cells exchanging genetic material
through these filamentous structures. This hyphae form is also associated with pathogenicity and
biofilm formation. The exact cause of virulence in C. albicans is not fully understood but is
linked to the cells ability to adhere to cell surfaces and to induce tissue damage with the secretion
of hydrolytic enzymes (Douglas & Konopka, 2016). As these virulence traits are linked to
hyphae morphology, the basic cellular mechanics for this morphology are important.
F- and G-actin
Actin is an important cytoskeletal element in eukaryotic cells. Actin is found in one of
two forms: G-actin, which are monomeric actin subunits and F-actin which are composed of
monomeric actin subunits that have assembled to form a two-stranded filamentous structures
(Dominguez & Holmes, 2011). Actin can be found in both cortical patches and cables at
different stages of cellular development. Many key cellular functions rely on actin such as
vesicular transport, organization and positioning of cellular organelles, organelle segregation in
mitosis, and whole cell mobility. Actin has also been identified in both the cytoplasm and the
nucleus (Moseley & Goode, 2006). Key to actin function is its interaction with actin-related
proteins including those involved in actin crosslinking, capping, severing, and polymerization
and depolymerization events. The dynamics of actin within the cell is related to proteins that can
polymerize and reorganize actin. In fungi for example, the actin binding proteins Arc35 and Sla2
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are important for cellular uptake by endocytosis; Arp2/3 and Sac6 are associated with vesicle
transport along actin cables; the Arp2/3 complex plays a key role in the nucleation of actin for
the formation of actin patches; and Bnr1 is an essential protein for the assembly of actin cables
(Amberg, 1998; Dominguez & Holmes, 2011; Galletta, Mooren, & Cooper, 2010; Moseley &
Goode, 2006). Additional actin associated proteins with important cellular functions are
members of the myosin family. Myo3 and Myo5 are members of the myosin type I family and
have a role in endocytosis and cortical patch formation (Oberholzer, Marcil, Leberer, Thomas, &
Whiteway, 2002). There are also two type V myosin proteins, Myo2 and Myo4, responsible for
the transport of vesicles along actin filaments (Galletta et al., 2010). Disruption of actin, actin
binding proteins, or myosin activities negatively impacts normal cellular functions and have
profound effects on cell viability (Moseley & Goode, 2006).
Actin is a highly conserved protein. Actin from C. albicans has a 94% sequence identity
to S. cerevisiae and 84% amino acid identity to muscle actin from Homo sapiens (NCBI protein
BLAST). In yeast there is only one gene that codes from actin, ACT1. In contrast, Homo sapiens
have six different genes coding for six isoforms of actin, all having a high degree of sequence
conservation between them (Perrin & Ervasti, 2010). Two of these isoforms are found in all cell
types while the four remaining isoforms are expressed only in muscle cells (Perrin & Ervasti,
2010). Although all isoforms can assemble to form actin filaments, roles for each of these
isoforms may be specific to the cells where they are found.

.
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Actin and hyphae formation
The most basic mechanism driving morphological switching is polarized cell growth.
Fundamental to polarized growth is the organization of the actin cytoskeleton. Actin is seen in
patches localized to the plasma membrane at sites of secretion (Pukkila-Worley et al., 2009).
These patches are often associated with polarized growth which further supports its relation to
the secretory pathway (Whiteway & Bachewich, 2007). Unlike mammalian cells which use
primarily microtubules for cellular transport, yeast cells use actin-based transport along actin
cables (Galletta et al., 2010). These F-actin cables direct the transport of proteins,
polysaccharides, and lipids through the activity of myosin type V proteins (Kachurina, Turcotte,
& Whiteway, 2012). The transport to these polarized areas of cell growth is also dependent on
myosin type I proteins which mediate cortical patch formation. The control of cellular actin
organization is regulated by Rho proteins which create polarized growth and maintain hyphae
extension (Dunkler & Wendland, 2007). Cortical patches of actin are normally observed at the
site of budding, hyphae formation, and the tip of growing hyphae. Likewise, actin cables are
normally focused to the sites of polarized growth and down the growing hyphae filaments
(Moseley & Goode, 2006). Two signaling cascades play an important role in the switch to
filamentous growth: the Ras1p and Cyr1p signaling pathways (Sudbery, 2011). Each of these
pathways relays the cell signal to turn on hyphae specific gene expression. Many aspects of
initiation and maintenance of filamentous growth depend on actin function. An example of this
has been shown with the Wal1 protein which in C. albicans is a homolog to the Wiskott-Aldrich
syndrome (WASP) which is known to regulate formation of actin filaments and cytoskeletal
organization (Walther & Wendland, 2004). Mutants of this protein have a disruption in cell
polarization and are unable to produce hyphae under the conditions tested. Other proteins whose
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loss of function are linked to hyphae defects include Efg1p, Cph1p, and Tup1p, all of which are
transcription factors (Douglas & Konopka, 2016). Each of these deletion mutants have been
shown to lack the ability to invade and damage host tissues. This data supports that C. albicans
that are unable to attain a filamentous morphology have attenuated virulence, highlighting the
importance of actin and the ability to reorganize actin architecture to induce morphological
switching.
Antifungal compound activity in C. albicans
Compounds that result in fungal cell death are considered fungicidal, while those that
impair fungal growth are fungistatic. Both are considered as having antifungal properties. The
two most common family of antifungals used to treat C. albicans are azoles and echinocandins
(Hawser & Islam, 1999). Azoles, such as fluconazole, are a class of drugs that inhibit the
conversion of lanosterol to ergosterol by disrupting activity of fungal demethylase encoded by
ERG11 (Hawser et al., 1996). While ergosterol is an important component of the plasma
membrane, azoles are fungistatic in C. albicans. The data also indicated that only at very high
concentrations of azoles was the induction of hyphae formation blocked. The second commonly
used antifungal compounds are in the echinocandin family and include Caspofungin and
Mulundocandin, which noncompetitively inhibit beta-1,3-D-glucan synthase activity (Hawser &
Islam, 1999). The crosslinking of glucans is key to cell wall strength. The lack of beta-glucan
activity therefore reduces cellular resistance to osmotic forces that can result in cell death. This
family of antifungals is fungicidal in C. albicans. While resistance to this family is rare, some
organisms have recently developed resistance by upregulation of efflux pumps, induction of
alternative glucan synthesis mechanisms, or utilizing chitin to reinforce the cell wall (Perlin,
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2015). Research has shown that echinocandins will block the initiation of hyphae formation at
doses well below the normal MIC for cells in their yeast form (Hawser et al., 1996).
Occidiofungin
Occidiofungin is a novel, naturally occurring secreted peptide that is extracted from
liquid cultures of Burkholderia contaminans MS14, a bacterium that is ubiquitous in the
environment (Lu et al., 2009). This peptide is not synthesized by ribosomes, rather it is produced
through the activity of multiple enzymes including transferases, dehydratase, nonribosomal
peptide synthetase, and polyketide synthetase (Lu et al., 2009). Occidiofungin is a cyclic
molecule containing 8 amino acids, a fatty acid group, and a xylose sugar (Gu, Smith, Liu, & Lu,
2011). This compound has a broad antifungal activity against both plant and mammalian
pathogens including Candida spp., Aspergillus spp., and Microsporum gypseum (Emrick et al.,
2013). Interestingly, occidiofungin can target Pythium spp. and Cryptococcus neoformans, fungi
that lack ergosterol and chitin or exhibit resistance to echinocandins, suggesting that
occidiofungin mode of action is different than current antifungal agents (Lu et al., 2009).
In previous studies using Saccharomyces cerevisiae, occidiofungin was shown to induce
apoptotic cell death as evidenced by the accumulation of DNA damage, reduction in cell size,
and elevation in reactive oxygen species (Emrick et al., 2013). Additional work supports
occidiofungin susceptibility being linked to active cellular growth as cells in quiescence were
resistant to occidiofungin exposure. The addition of extracellular divalent cations also created an
environment that lead to resistance (Robinson, Denison, Burkenstock, Nutter, & Gordon, 2017).
Toxicologically, occidiofungin is well tolerated in a murine model at 1mg/kg dosing regimens.
Though toxic effects such as organ weight loss were seen at extremely high doses (20mg/kg)
(Tan et al., 2012). Overall, occidiofungin was shown to be non-toxic at doses that are consistent
11

with ranges for treatment of fungal infections. Occidiofungin was also shown to remain stable in
low pH environments (Ellis et al., 2012) , which is important for any oral applications. These
initial studies suggest that occidiofungin could be a viable antifungal treatment.
Hypothesis
An important step in determining whether a compound can function as a new form of
antifungal treatment is understanding what it does to the target organism. In this project I seek to
address this question by characterizing the morphological changes that result with occidiofungin
exposure using the pathogenic yeast, Candida albicans, as the model fungi. Cells will be
exposed to different doses of the compound and the effects on morphology and viability
analyzed using various microbiological and cell biological assays. Given that prior work had
demonstrated that the impact of occidiofungin on the yeast form of C. albicans could be
identified by biochemical and morphological changes, (Emrick et al., 2013), I hypothesize that
occidiofungin treatment of cells at the point of switching will also give rise to visible
morphological defects that can be characterized.

12

CHAPTER III
MATERIALS AND METHODS
Yeast strain
C. albicans strain, ATCC 66027, was used for all described studies. Working cultures
were generated by streaking cells from a -80˚C freezer stock to a YPD agar plate which was
incubated at 30˚C for 24 hours. Cells were taken directly from this plate for the inoculation of
liquid cultures.
Yeast media
For vegetative growth, C. albicans was maintained at 30˚C in YPD media (1% yeast
extract, 2% peptone, 2% dextrose). To induce hyphae formation, cells were diluted into Spider
media (1% nutrient broth, 1%mannitol, 0.2% K2PO4) and placed at 37˚C.
Reagents
A 2mg/ml stock of Concanavalin A (Sigma, L7647) was made in sterile water and used
directly to coat glass slides for microscopy purposes. Calcofluor White (Sigma, 18909) was used
without dilution to stain fixed cells for chitin. Rhodamine labeled phalloidin (Sigma, P1951) was
dissolved in 100% DMSO to achieve a 3.3mM stock solution and used at 1:500 dilution for actin
visualization by fluorescence microscopy. A 20mg/ml stock of Resazurin (Sigma, R7017), made
in sterile water, was used at 50µg/ml in YPD or Spider media for microdilution MIC assays to
identify wells with cellular activity/growth. Trypan Blue (Sigma, T8154) was used directly to
monitor cell viability by dye exclusion. Vecta Shield with DAPI (Vector Labs, H-1200) was used
at 50% as an antifade agent for fluorescence microscopy and nuclear DNA stain.
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Antifungal compounds
All stock and working dilutions of antifungal compounds were made in 100% DMSO and
stored at -20˚C until needed. Occidiofungin was purified as described ((Wang et al., 2016); a gift
from Dr. Leif Smith). Stock and working solutions of occidiofungin included: 1mg/ml, 0.4
mg/ml, and 0.1mg/ml. Caspofungin was purchased from Sigma (SML0425) and dissolved in
DMSO to obtain a 1mg/ml stock solution. Working solutions of 0.4mg/ml and 0.05mg/ml were
made by subsequent dilution. Fluconazole (Sigma, F8929) stock was made at 200mg/ml with
100mg/ml and 8mg/ml working solutions.
CFU and spotting protocol
A saturated culture of C. albicans ATCC 66027 was obtained by inoculating 20mls of
YPD with cells taken from a fresh streak plate and the culture maintained at 30˚C with shaking
for 48hrs. The resulting cell density was determined by optical density reading at 600nm after
step diluting the culture 1:40 in YPD (Sittampalam et al., 2018). To obtain a working culture,
cells were diluted in Spider media to achieve a 0.05 OD600/ml. The culture was divided into two
equal groups; one was treated with the antifungal compound (occidiofungin at 0.25µg/ml to 1
µg/ml, fluconazole at 7.8µg/ml, and caspofungin at 0.1µg/ml) and the second was the control
group treated with an equivalent volume of DMSO. Aliquots were removed from each treatment
at set time points in a 0 to 6-hour window. Samples were 5-fold serially diluted in Spider media
in 8-strip polypropylene PCR strips (Applied Biosystems, N8010580) to avoid cell adhesion
which occurs in standard polystyrene microtiter plates. Samples (80µl) were placed in the first
well of each strip and 160µl of media placed in wells 2 through 8. The serial dilution was
performed by transferring 40µl across all wells in the strip. For spotting assays, 3µl volume from
each well was spotted to a YPD agar plate and the plates incubated at 30˚C. All spotting was
14

done in duplicate for all time points. Images were taken after 24hr and 48hr of growth. For
colony forming unit (CFU) determination a 50µl volume was taken from select wells of the
dilution series and spread over a YPD agar plate. Three wells were selected for each sample and
three 50µl aliquots were plated per well (Robinson et al., 2017). The plates were incubated for 48
hours at 30˚C. After incubation the number of colonies on each plate were counted (Heathrow
Scientific eCount Colony Counter) and recorded.
Cell morphology by light microscopy
C. albicans cells were grown to saturation, diluted, and divided into experimental groups
as described above. At each treatment time point, 250µl to 500µl of sample was removed and
fixed with the addition of 37% formaldehyde to 3.7% final. At a later date, samples were
centrifuged at 8000 xg for 10 minutes to pellet cells, the formaldehyde removed, and the cells
resuspended in 30µl of 1XPBS. An aliquot of cells was combined with an equal volume of
VectaShield with DAPI and 3.5µl of this mixture was placed on a concanavalin A treated glass
slide. Cells were viewed using a Nikon Eclipse-50i microscope and images recorded by QCapture Pro software.
Samples were evaluated for morphology based on previously published metrics for C.
albicans by Merson-Davies and F.C. Odds (Merson-Davies & Odds, 1989). All cells were placed
into one of two categories: yeast form or hyphae form. Cells scored as “yeast” were spherical
shaped cells that may or may not possess a bud. Cells scored as “hyphae” were spherical cells
with a long-septate extension from a polarized location. Any cell that possessed a hyphae-like
structure were the septum was undetached from the main cell body was binned as yeast form.
Cell count numbers were recorded from images obtained using the 100X objective with a
minimum of 200 cells analyzed per condition and time point.
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Fluorescence microscopy of mannans, chitin, and actin
For mannan and chitin staining, cells were grown and separated into experimental groups
as described in the light microcopy section above. At selected time points, 500µl to 800µl of
sample was removed and fixed with the addition of formaldehyde to 3.7% final. The cells were
isolated by centrifugation and the cell pellet resuspended in Vecta Shield as described above. For
mannan staining, 10µl of cells were treated with 10µl of FITC labeled concanavalin A for 5
minutes at room temperature. Unbound concanavalin-A was removed with a 1XPBS wash prior
to viewing on a glass slide (Hoch, Galvani, Szarowski, & Turner, 2005). For chitin staining, cells
were added to an equal volume of calcofluor white and incubated at room temperature for 5
minutes prior to addition to a concanavalin A treated slide. Data was collected using a Nikon
Eclipse-50i microscope with fluorescent filters for DAPI and calcofluor white (UV-2E/C) and
concanavalin-A (B-2E/C FITC). Images were collected using Q-Capture Pro software with the
same exposure settings.
Cell staining to visualize actin was carried out as described (Ravichandran et al., 2019)
with the following modifications. Samples were fixed in 3.7% formaldehyde at room
temperature for 1.5 hours and cells isolated by vacuum filtration using a 0.2µm nitrocellulose
filter. Cells were resuspended in 250µl of 1XPBS, permeabilized with the addition of an equal
volume of 0.2% TritonX-100 in 1XPBS and stained with the addition of 1 µl of 3.3mM
rhodamine-phalloidin for 30 minutes at room temperature. Cells were isolated by centrifugation
at 6000 xg for 10 minutes at room temperature and the solution removed. The cell pellet was
resuspended in 1XPBS and an equal volume of VectaShield with DAPI was added. Cells were
visualized using the 100X objective (N.A. 1.25) with a Nikon Eclipse-50 microscope with
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fluorescent filters for rhodamine (FL Y-2E/C). Images were capture using QCapture Pro
software.
MIC Assay of Antifungal Compounds
A culture of C. albicans ATCC 66027 was grown to saturation. Cells were diluted into
Spider media to achieve an OD600 of 0.05 (equivalent to 1.6 x 106 cells/ml), 1 x 104 cells/ml, or 1
x 105 cells/ml. Resazurin salt was added directly to the diluted cell cultures to achieve 50µg/ml
final concentrations. Cells were placed in a 96 well plate such that well 1 had 200µl of culture
and wells 2-12 had 100µl of culture. The antifungal agents were added to the cells in well 1 and
then serially diluted 2-fold with the transfer of 100µl of across all wells (Ellis et al., 2012). The
range of antifungals used included: occidiofungin 2µg/ml to 0.9ng/ml; caspofungin 2µg/ml to 0.9
ng/ml; and fluconazole 125µg/ml to 0.06ng/ml. Plates were incubated at 37˚C for 24 and 48
hours. Wells where the color changed from purple to pink were noted. Plate images were
photographed and the 1X MIC and 0.5X MIC points recorded. Fluconazole presents in this assay
with a “trailing” effect (Manavathu, Cutright, & Chandrasekar, 1998), a partial color change
above the MIC value due to it being fungistatic rather than fungicidal. Only with the complete
lack of metabolic activities seen with cell death does a color change not occur.
Calculations
Measurements were obtained for hyphal length from cell images using NIH ImageJ
software and measured with in programs features. The size bar was used as the calibration
standard. The percent cell death was calculated by the difference between average CFU per ml
for treated groups and its matching untreated group as previously described (Robinson et al.,
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2017). CFU calculations were based on number of colonies counted per plate multiplied by the
dilution factor for the plate and corrected by the volume of culture plated to achieve 1ml.
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CHAPTER IV
RESULTS
Occidiofungin activity against filamentous C. albicans
Occidiofungin has been shown to be an effective fungicidal agent against vegetative
growing C. albicans (Robinson et al., 2017). However, as the virulent form of C. albicans is
primarily when it is in its filamentous form (Pukkila-Worley et al., 2009), the efficacy of
occidiofungin against this form of the yeast must be demonstrated before considering its
therapeutic potential. To characterize the impact of occidiofungin against cells induced to
undergo morphogenic switching, MIC assays were carried out under switching conditions. As
cell numbers are not expected to significantly change under these conditions, and to ensure that
wells with viable cells could be easily identified, resazurin was included in the switching media.
The resazurin indicator undergoes a color change from blue to pink as a result of the irreversible
reduction of resazurin to resorufin during aerobic respiration and is therefore be used to identify
wells that have metabolically active cells (Elshikh et al., 2016). Under these conditions, the MIC
well was identified as the well containing the lowest drug concentration that did not exhibit any
change in color (Figure 4.1). At the concentration used, resazurin was shown to have no negative
impact on MIC determination (data not shown). Assay results are presented in Table 4.1 and a
representative MIC assay carried out in the presence of resazurin is shown in Figure 4.1.
Clinical laboratory standards for MIC determination of antifungal susceptibility are
carried out using a protocol that results in an estimated cell density of ~1.0 x 104 cells/ml. As cell
density significantly impacts switching efficiency of C. albicans, MIC assays were carried out on
cells over a range of cell densities including: 1.0 x 104 cells/ml, 1.0 x 105 cells/ml, and 1.6 x 106
cells/ml. Data showed that when added at the time of switching, occidiofungin exhibited an MIC
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value of 0.125µg/ml at the CLSI standard cell density of 1.0 x 104 cells/ml. This is 4-fold lower
than the corresponding MIC for the same number of cells growing in their yeast form (Robinson
et al., 2017). Not surprisingly, an increase in cell density required a higher dose of occidiofungin
for full fungicidal activity (Table 4.1).
The effect of other known antifungals on morphologically switching cells has been tested
by others (Hawser & Islam, 1999) and were carried out in parallel to directly compare to
occidiofungin activity. Antifungals in the azole (fluconazole) and echinocandin (caspofungin)
family were tested. When exposed to fluconazole under switching conditions, a “trailing effect”
was observed using resazurin in the MIC assay (Manavathu et al., 1998). The “trailing” effect is
due to fluconazole having fungistatic activity which results in viable, but slow growing cells that
lead to a partial color change compared to no color change for a fungicidal compound. The
echinocandin, caspofungin, exhibited an MIC value of 0.031µg/ml for cells at a density of
1.6x106 and 1x 105 cells/ml. Surprisingly, cells at the lowest density tested were found to have a
higher tolerance to caspofungin with an MIC value of 0.062µg/ml.
To take a quantitative approach towards measuring the impact of occidiofungin on C.
albicans at the time of morphological switching, colony forming units (CFU)-based experiments
were undertaken. Cells were grown, treated, and plated as follows. Cells from a saturated culture
were diluted into fresh Spider media to achieve a cell density of 0.05 OD600/ml. The culture was
split, with one half of the cells receiving the antifungal at the concentration noted, and the other
half receiving an equivalent volume of DMSO. Cells were placed at 37˚C to induce switching
and samples removed at defined time points for serial dilution and plating. The data was first
analyzed by plotting log10 CFU number versus time of exposure (Figure 4.3). Cells that were
treated with DMSO as a control showed a short lag phase before a slight change in colony
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number was detected. With an average of only a 5.4% increase in cell number over the 6-hour
period (n=3) this likely reflects the ~10-15% of the cell population retained in the yeast form that
entered back into the cell cycle. In contrast, cells treated with occidiofungin showed a rapid
decline in colony number that is what would be expected for a fungicidal compound. The data
was further analyzed to determine percent cell death at each of the time points tested (Table 4.2).
Over the three experimental trials, occidiofungin treated cells showed a large increase in cell
death following two-hour exposure time which continued over the 6-hour exposure time. The
lack of high levels of cell death in the first two hours after exposure is an expected finding as
previous experiments had shown that cells that are not actively growing are more resistant to
occidiofungin (Robinson et al., 2017). The cultures used here were grown to saturation before
being placed into fresh media to induce switching. As the cell numbers for both treated and
untreated were similar over the first two hours, this suggests that the cells require time to activate
reentry back into an actively growing phase which makes them more susceptible to
occidiofungin.
Spotting assays were also run in parallel with the CFU assays to qualitatively visualize
the effects of occidiofungin. Data from these assays confirmed that prior to exposure to
occidiofungin, both treated and untreated samples showed an identical growth pattern (Figure
4.3). However, for all later time points a visible reduction in growth was detected for
occidiofungin treated cells. This data matches the CFU and MIC assay results, supporting
occidiofungin’s fungicidal activity in switched C. albicans cultures.
Impact of 1.0X MIC dose of occidiofungin on C. albicans filamentation
Cell morphology has been shown to be linked to invasion and cell damage (Phan,
Belanger, & Filler, 2000). As different antifungal compounds have variable effects on the cells
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ability to induce filament formation, this creates a necessity to test what effects occidiofungin
will have on cell morphology when used at the point of switching. To access the effects of
occidiofungin on the morphology of C. albicans during morphological switching, cells were
analyzed by light microscopy. As expected, cells that were scored immediately after being
placed into switching conditions (T=0) were all in their yeast form (Figure 4.4). For the untreated
group, after one hour in switching conditions ~56% of the population was in a yeast form while
the remaining cells had hyphae. Over 2- and 4 hours in switching conditions, there was a
continued increase in cells that had filamentous extensions with an average of 82% and 87% of
the cells in the population exhibiting hyphal growth, respectively. However, by the 6-hour time
point there was an increase in the population of cells in the yeast morphology (~38%) which
likely represents the fact that the yeast cell populations are undergoing cell division (Figure 4.5).
For cells that had been treated with occidiofungin, the population remained primarily in the yeast
form over the 6 hours of the experiment; cells with hyphal extensions were rarely found (<1%).
As occidiofungin was used at a concentration equivalent to 1X MIC, cells were also analyzed by
live/dead assay using trypan blue to calculate the percentage of viable cells in the population. By
this assay, at least 60% of the cells on each slide were viable cells for all time points. Together,
this data suggests that occidiofungin exposure at the time of morphological switching interferes
with a cell’s ability to form a hyphal extension.
Occidiofungin at 0.5X MIC disrupts normal hyphae formation
Cells treated with antifungal compounds will commonly have cellular morphology
abnormalities including changes to cell size, composition of cell wall components, and
alterations to shape of cellular structures (Hawser & Islam, 1999). To determine if this was the
case for occidiofungin, the impact of the compound was tested using a sublethal MIC dose for
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switching cells to better characterize effects on morphology. Cells were treated at the time of
switching with a 0.25µg/ml occidiofungin and collected at set times following exposure, with
cells fixed for viewing by light microscopy (Figure 4.6 and 4.8). As expected, at the zero-hour
time point 100% of the treated and untreated cells had the yeast morphology. In the untreated
group at the one-hour time point, the majority of cells were found in their filamentous form
(94%), while in the treated group, ~86% of the cells were in the yeast form with only 14%
having a hyphal morphology. For the treated group the number increased to 75% of the
population having filaments by 2 hours with very little change at the 4 hour and 6 hour time
points (Figure 4.7). This data showed that when treated with a sublethal dose of occidiofungin,
the cells could induce filamentation however fewer cells in the population were able to switch
and the time needed for hyphal development required an additional hour to visually detect.
Along with the shift in time needed for switching, defects in the hyphae produced were
seen at nearly every time point. The most obvious defect that was seen was a large reduction in
the length of the filaments formed (Figure 4.8). The untreated group saw a steady increase in
hyphal length over time, with an average length of ~23 microns at two hours and ~65 microns by
four hours. This was approximately a 2.8-fold increase in length over the 2-hour period. For the
occidiofungin treated group, cells have filaments of ~6 microns at two hours and ~10 microns at
four hours (Figure 4.9). This represents only a 1.6-fold increase over the same period of time.
This data highlights the fact that occidiofungin negatively impacts the ability of the cell to
organize and grow normal hyphae structures.
The second abnormality that was identified was in the hyphal shape displayed during
growth (Figure 4.10). When a normal hypha is formed there is symmetrical growth outward from
the body to the hyphal tip (Sudbery, 2011). At two-hour time point, cells were identified that had
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asymmetrical growth at the tip which produced a hyphae “bloat” at an average percent of 31%
(Table 4.3). This abnormally began to decline by the 4-hour time point and was only seen in
small numbers at six hours. However, at the six-hour time point, branching was noted in
approximately 9.5% of cells (Table 4.3). The total percent of the population that presented with
morphological abnormalities was determined for the 6-hour exposure time and the data presented
in Table 4.3. These atypical hyphae growths suggest a disruption in the cells ability to control
polarized cell growth.
Occidiofungin exposure has no effect on cell wall composition
Antifungal compounds create damage that requires changes in the cell wall composition
(Hawser & Islam, 1999). Some common signs of cellular stress are upregulation of chitin and
changes in mannan distribution in the cell wall. As occidiofungin was shown to upregulate chitin
expression in yeast grown cells the impact of the antifungal on cells undergoing hyphal
formation was determined (Emrick et al., 2013). Cells were exposed at the time of switching to
1.0X MIC dose of occidiofungin and cells were stained with calcofluor white to identify chitin or
cancanavalinA-FITC to identify cell wall mannans. Unlike what was seen for yeast grown cells,
no changes in the amount or localization of chitin was detected (Figure 4.13). Similar to what
was observed previously (Ellis et al., 2012), no changes in mannan distribution were identified
for occidiofungin exposed cells induced to undergo morphological switching (Figure 4.12).
C. albicans cells exposed to 1.0X MIC dose at the time of switching disrupts actin
organization
Actin is a key structural component of the cell responsible for several steps involved in
hyphae formation (Sudbery, 2011). Actin reorganization into cortical patches is a major step in
establishing cell polarity for hyphae growth and the formation of F-actin cables is needed for
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proper growth of the filamentous structures (Dominguez & Holmes, 2011). Finally, actin is a key
part of the Spitzenkorper, a formation in the tip of the hyphae responsible for polarized
elongation, which must be maintained for proper symmetrical growth (Sudbery, 2011). To look
at the impact that occidiofungin has on cellular actin organization, cells were treated with a 1.0X
MIC dose of occidiofungin at the point of switching and Rhodamine labeled phalloidin was used
to visualize actin in cells at various stages of occidiofungin exposure. In untreated cells, actin
could be detected as small actin patches generally distributed throughout the unbudded cells.
After 1hour, the small actin patches started to organize into brighter patches (Figure 4.14 A).
These patches become the concentrated area for filament formation by 2 hours and finally
formed a bright actin patch at the tip of the hyphae (Figure 4.14 C). In contrast, cells that were
exposed to occidiofungin never reorganized their actin having only small punctate patches
through the cell body (Figure 4.14 B). This lack of any reorganization to the actin architecture is
likely the reason behind the absence of hyphae formation in these cells.
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2-Fold Dilution of Antifungal

Caspofungin

Caspofungin
Well 1: 2.0 µg/ml

Fluconazole

Fluconazole
Well 1: 500 µg/ml
Occidiofungin
Well 1: 2.0 µg/ml

Occidiofungin

Figure 4.1

Resazurin MIC Assay

Concentration dependent antifungal activity of Occidiofungin, Caspofungin, and Fluconazole.
Assay performed in YPD for 48 hours at 37˚C with resazurin metabolic activity indicator. A
change in color from blue to pink indicates metabolic activity associated with viable cells. The
MIC value is the well that has the lowest dose of antifungal that retains its blue color. Red boxes
indicate the 1.0X MIC dose.
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Table 4.1

Antifungal Sensitivity

Antifungal
Occidiofungin
Caspofungin
Fluconazole

104 cells/ml
0.125µg/ml
0.062µg/ml
3.9mg/ml

105 cells/ml
0.25µg/ml
0.031µg/ml
7.8mg/ml

106 cells/ml
1.0µg/ml
0.031µg/ml
>12.5mg/ml

Antifungal sensitivity is cell density dependent. Cells from a 48hr saturated culture were diluted
into Spider media to achieve 1x104, 1x105, or 1.6x106 cells/ml for use in a microtiter-based MIC
assay. Resazurin was included to identify wells with viable cells. The MIC value was identified
as the well with the lowest concentration of antifungal that inhibited growth. Data from 3
independent experiments are shown.
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5X serial dilution
T=0 hr
DMSO
+ Occ
T=4 hr
DMSO
+ Occ
Figure 4.2

Spotting Assay for Cell Growth

Cells from a saturated culture of C. albicans were diluted into Spider media with occidiofungin
(1.0X MIC) or vehicle control (DMSO) and placed at 37˚C. Samples were removed at the
indicated time points, 5-fold serially diluted, and spotted to YPD. Photos were taken after 24hr48hr of growth at 30˚C. A representative image is shown.
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Occidiofungin

5.1
4.6
4.1
3.6
0

Figure 4.3

2

4
Exposure Time (hours)
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Cell Growth Analysis by Colony Forming Unit Assay

Cells were placed in switching media to achieve a density of 0.05 OD600/ml. DMSO or
occidiofungin at 1.0X MIC (1.0µg/ml) was added T=0. Samples were removed at defined time
points over the 6hr period, serially diluted, and select sample dilutions spread onto YPD plates (3
plates/well; 2-3 wells/treatment regime). Following 48hr of growth at 30˚C the number of
colonies per plate were determined. The colony forming units per ml was calculated and the data
plotted for each time point analyzed.
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Table 4.2

Percent Cell Death

Time (hr)
0

-0.11 ± 0.58 (n=3)

1

4.82 ± 3.74 (n=3)

2

1.69 ± 1.09 (n=3)

4
6

18.32 ± 8.23 (n=3)
31.75 ± 9.53 (n=3)

Percent cell death induced by occidiofungin exposure. Values determined based on the
accumulated CFU data, collected as described in Figure 4.3 for 3 independent experiments.
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Figure 4.4

Morphology of C. albicans by Light Microscopy

Cells from a saturated culture were diluted into fresh media to achieve a cell density of
0.05OD600/ml. Occidiofungin (A, C, E, and G) at 1X MIC dose (1.0 µg/ml) or DMSO (B, D, F,
and H) was added and samples incubated at 37˚C to induce switching. Aliquots were removed at
0hr (A, B), 1hr (C, D), 2hr (E, F), and 4hr (G, H) post switching for visualization by 100X light
microscopy. Size bar= 5µm
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DMSO, yeast

DMSO, hyphae

Occidiofungin, yeast

Occidiofungin, hyphae

Percent Morphology 1.0X MIC

Occidiofungin prevents morphological switching of C. albicans. Cells were prepared as
described in Figure 4.4. The percentage of cells in the population having either a yeast (open
circles) or hyphae morphology (filled triangles) were calculated. At least 200 cells were counted
for each time point. The average and standard deviation for data collected from 4 independent
experiments is shown.
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Figure 4.6

Percent Morphology of C. albicans 0.5X MIC

Cells from a 1 x 105 cells per ml culture were induced to switch with fresh media and incubated
at 37˚C with samples taken at hour-based time points. A montage where A) T=0 hours untreated,
B) T=0 hours, 0.5X MIC occidiofungin treatment, C) T=4 hours, untreated, D) T=4-hour, 0.5X
MIC occidiofungin treatment. Size bar = 5µm
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Occidiofungin delays morphological switching. At a sublethal dose, cells were prepared as
described in Figure 4.4 except the occidiofungin was used at 0.5X MIC 0.25µg/ml and culture
are 1 x 105 cell/ml. The percentage of cells in the population that were yeast (open circles) or
hyphae (filled triangles) were determined. At least 200 cells were counted for each time point per
group. The average and standard deviation for data collected from 4 independent experiments is
shown.
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Figure 4.8
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T=2 hours

F

T=4 hours

Hyphae Length Comparison 0.5X MIC

Cells from a saturated culture were diluted into Spider media to achieve a density 1x105 cells/ml.
The culture was split with one sample receiving occidiofungin at a dose of 0.25µg/ml (0.5X
MIC) and the other an equivalent volume of DMSO. Cells mounted with Vecta shield on glass
slides and viewed by 100X light microscopy. An example image characteristic of cells at the
indicated time points are shown for untreated (A, C, and E) and occidiofungin treated (B, D, and
F) cells at 1, 2, and 4 hours post switching. Size bar = 10 µm.
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Figure 4.9

Hyphae Length Graph 0.5X MIC

A sublethal dose of occidiofungin slows hyphae formation. Hyphae length in untreated and 0.5X
MIC occidiofungin treated cells were determined for cells processed as described in Figure 4.8.
Hyphal lengths were measured using NIH ImageJ with a minimum of 50 cells per time point per
sample. Data for the average and standard deviation from 2 independent experiments are shown.
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Figure 4.10

Morphological Defects 0.5X MIC

C. albicans cells treated with a sublethal dose of occidiofungin as viewed by light microscopy.
Cells from a saturated culture were diluted into Spider media to achieve a density 1x105 cells/ml.
The culture was treated with 0.25µg/ml occidiofungin (0.5X MIC) for 2 hours. A montage of cell
that exhibited loss of polarized tip growth resulting in “hyphal tip bloat” are shown. Cells with
these morphological defects make up ~30% of the population at this time point. Size bar=10 µm.
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Figure 4.11

Morphological Defects 0.5X MIC

C. albicans cells treated with 0.25µg/ml occidiofungin (0.5X MIC) at the time of switching as
viewed by light microscopy. Cells from a saturated culture were diluted into Spider media to
achieve a density 1x105 cells/ml and maintained in the presence of the antifungal compound for
6 hours. Cells exhibiting a loss of polarized hyphal growth which includes hyphal bloat and the
formation of multiple filaments are shown. These morphological defects make up ~3% and ~9%
of the cell population, respectively. A montage of images from 2 independent experiments are
shown (A and B). Size bar=10 µm.
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Table 4.3

Total Morphology Defects 0.5X MIC

Time
Point

11-11-18

11-18-18

Average(n=2)

T=1 hr

Hyphae Bloat: 3
Abnormal Hyphae
Branching: 0

Hyphae Bloat: 3
Abnormal Hyphae
Branching: 0

Hyphae Bloat: <0%
Abnormal Hyphae
Branching: 0%

T=2 hr

Hyphae Bloat: 106
Abnormal Hyphae
Branching: 0

Hyphae Bloat: 67
Abnormal Hyphae
Branching: 0

Hyphae Bloat: 31%
(+/- 15%)
Abnormal Hyphae
Branching: 0%

T=4 hr

Hyphae Bloat: 1
Abnormal Hyphae
Branching: 11

Hyphae Bloat: 26
Abnormal Hyphae
Branching: 7

Hyphae Bloat: 5% (+/- 6%)
Abnormal Hyphae
Branching: 3.5% (+/-1%)

T=6 hr

Hyphae Bloat: 1
Abnormal Hyphae
Branching: 45

Hyphae Bloat: 18
Abnormal Hyphae
Branching: 18

Hyphae Bloat: 3% (+/-4%)
Abnormal Hyphae
Branching: 9.5% (+/- 4%)

Total cell counts: 11-11-18 T=1 (135); T=2 (255); T=4 (258); T=6 (354)
11-18-18 T=1 (493); T=2 (330); T=4 (259); T=6 (293)

Hyphae abnormalities seen by light microscopy in C. albicans cells treated with 0.5X MIC
occidiofungin. Cells processed as described in Figure 4.10. The total number of abnormality
types identified, and their average percent of the total cell population are presented. Data
acquired from 2 independent experiment; standard deviation.
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Figure 4.12

B
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Mannan Distribution 1.0X MIC

C. albicans cells induced to undergo morphological switching visualized by concanavalinAFITC. Cells diluted into Spider media to promote hyphae formation were treated with
occidiofungin (1X MIC 1.0µg/ml) in a culture of 0.05 OD600 (B) or with an equivalent volume of
DMSO (A, C). Samples were collected at T=0hrs (A) and 4hrs (B, C), fixed in formaldehyde,
followed by treated with concanavalinA-FITC. Cells were visualized by immunofluorescence
microscopy using 100X magnification. Size bar = 5 µm.
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Figure 4.13

B

C

Chitin Distribution 1.0X MIC

Fluorescence microscopy of cells stained by calcofluor white. C. albicans cells induced to
undergo switching were treated with occidiofungin (1.0X MIC 1.0 µg/ml) in a culture 0.05
OD600 (B) or DMSO, the vehicle control (A, C). The distribution of chitin was determined for
untreated cells at T=0hrs and cells exposed to occidiofungin (B) or DMSO (C) for 4 hours. Size
bar=5 µm.
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Figure 4.14

Actin Distribution 1.0X MIC

Fluorescence microscopy of actin treated and untreated cells by rhodamine-phalloidin staining.
C. albicans cells induced to undergo switching were treated with occidiofungin (1.0X MIC 1.0
µg/ml) in a culture 0.05 OD600 (B) or DMSO, the vehicle control (A). The distribution of actin
was determined for untreated cells at T=0hrs and cells exposed to occidiofungin (B) or DMSO
(C) for 4 hours. Size bar=5 µm.

42

CHAPTER V
CONCLUSIONS/DISCUSSION
The collection of data from these experiment helps establish occidiofungin as a potential
antifungal compound for the treatment of candidiasis. Opportunistic pathogens, such as C.
albicans, as natural components of the human microbiome pose a unique set of concerns. When
patients undergo a medical treatment that leaves their immune system in a compromised state,
limiting potential exposure to environmental pathogens can be accomplished. However, when
the pathogen is part of the natural flora it becomes impossible to simply limit exposure to prevent
infection. Having reliable choices in the treatment of these kinds of infections is an answer to
this problem.
The first important step in evaluating potential treatments is to determine how effective
the compound is at eliminating the target pathogen. Previous work has shown that the antifungal
compound, occidiofungin, was effective against the yeast form of the nonpathogenic fungi, S.
cerevisiae, as well as various Candida species (Emrick et al., 2013; Robinson et al., 2017). For
C. albicans to invade and damage host tissue it must undergo a morphological switch from the
yeast form into a filamentous morphology (Phan et al., 2000). This fact formed the basis for
these studies.
Multiple approaches demonstrated that occidiofungin was effective against cells that
were induced to undergo morphological switching. Specifically, MIC assays revealed
occidiofungin has dose- and cell density-dependent fungicidal activity. Most importantly, the
data found that the dose needed for antifungal activity was lower for cells undergoing switching
than that of cells in yeast form. CFU assays established that fungicidal activity occurred when
cells were in switching media for two hours. When this data is compared to data showing that
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yeast cells that are in quiescence show a higher resistance to occidiofungin (Robinson et al.,
2017), a link between cell growth and occidiofungin effectiveness can be made. Cells placed into
fresh media following growth to saturation likely require time for cells to activate cellular
activities to resume an active growth phase. This suggests a number of possibilities with regards
to occidiofungin bioactivity. It is possible that its cellular entry, which is still unidentified, is
mediated by the mechanics of cellular growth. It is also possible that the compound’s target is
only present, or only required for viability, when the cell is actively growing. When a cell has
switched to a filamentous morphology growth is polarized and focused to the tip of the hyphae
(Sudbery, 2011). A key part of the sustained growth in both filamentous and yeast morphology is
the recycling of material by endocytosis (Galletta et al., 2010). This increase in the amount of
material being taken up from outside could be a point of entry for occidiofungin. Thus, when
only minimal uptake or no uptake by endocytosis takes place, a reduced amount of compound
would gain entry to the cell resulting in a reduction in the effective action of the compound. A
return to active growth would lead to enhanced endocytosis and a lower dose of the compound
would be needed for fungicidal activity. The second possibility is that the target for
occidiofungin is only present or essential for viability when the cell is growing. For example,
some signaling pathways are only triggered by stimuli under specific conditions such as the
switch from yeast to hyphae morphology. This signaling pathway activates a specific set of
hyphae-related genes that may not be expressed otherwise (Sudbery, 2011). This ensures that a
cell is not expending energy on production of components that are not necessary or waste the
materials needed to synthesize them. In the case of occidiofungin, the fact that cells can be
targeted as yeast and hyphae suggests that the target would be present in both cell types.
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Having established that occidiofungin is effective against cells undergoing hyphae
switching, we next analyzed the impact on switching morphology. When exposed to a lethal dose
of occidiofungin, treated cells never formed hyphae over the 6-hour time frame of analysis.
Trypan blue staining confirmed ~60% of cells at 6hrs of exposure were viable, which means the
cells had the opportunity to undergo a morphological switch but were unable to. This data
suggests that the target within the cell for occidiofungin is essential for hyphae morphology.
While there is more than one target that meets both the active growth and hyphae formation
requirements, there is one very important element that is necessary for both: actin and its
associated proteins. Prior published work indicates that occidiofungin specifically targets actin,
binding to actin in in vitro assays and disrupting actin-based activities in in vivo studies
(Ravichandran et al., 2019). One of the key features of cellular growth is the delivery of material
to growing cell surfaces. Actin is a major player in both the uptake of extracellular materials for
growth and the delivery of those materials to the polarized areas of growth (Arkowitz &
Bassilana, 2011). When a cell exits quiescence, actin must be reorganized to both form the
cortical patches for endocytosis and provide the pathway for movement of materials by vesicle
transport. Thus, any disruption of the actin organization or protein movement along actin will
block the cell from the formation of a filament. This suggests that if occidiofungin blocks the
transition into filaments of even cells that are not killed by the initial dose, these remaining cells
will be unable to invade and damage tissues (Pukkila-Worley et al., 2009). From a treatment
standpoint, this would mean that less damage would occur in the time needed to resolve the
infection making the compound more attractive as a therapeutic.
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Prior work had demonstrated that S. cerevisiae cells have a loss of F-actin cables when
exposed to occidiofungin (Ravichandran et al., 2019). Based on these findings, the impact of
occidiofungin on C. albicans during morphological switching was analyzed in this study.
Normally when a cell begins filamentous growth, actin is reorganized from small cortical patches
that are evenly spread thought the cell surface to a central polarized patch (Sudbery, 2011). From
that patch, F-actin cables form that run the length of the filament with the central patch of actin
at the tip of the growing hypha. In cells exposed to a 1X MIC dose of occidiofungin, this
reorganization from small cortical patches to a central polar location failed to take place even
after six hours. This data confirms that actin organization is disrupted with occidiofungin
exposure. In cells exposed to a sublethal dose of occidiofungin data indicated that the timing of
switching (as determined by morphology) was delayed by around an hour. Whereas untreated
cells had a switchover (50% filament/50%yeast) 30 minutes following switching induction, in
cells exposed to sublethal levels of occidiofungin this switchover occurred approximately two
hours after placement in switching inducing conditions. In addition to altering the timing of
switching, fewer cells formed hyphae (80% versus 95-100% in untreated). This data suggests
that occidiofungin partially inhibited cells from making the switch to filamentous growth. This
may be because the lower dose allows some cells to compensate for the disruption in actin
dynamics before the damage is permanent. However, this compensation does not come without
consequences for the growing cells as C. albicans cells acquired morphological defects during
filament formation. This was identified as a loss of polarized tip growth which generated tip
“bloat”. This may be due to loss of polarized cell growth with addition occurring on the sides of
the hyphae as well as the tip. As discussed before, actin is a key element in the polarized delivery
to the growing filament tip (Sudbery, 2011). The loss of proper actin structures could result in
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either improper location of growing cell surface materials or the buildup of materials within the
hyphae without addition to the growing cell surface. Both of these events would result in
multidirectional expansion of the filament as opposed to polarized growth. This abnormality was
found to decrease over time which may suggest that these cells have rescued polarized growth
within this time frame. An additional morphological abnormality appeared which happened to
coincide with the reduction in the “bloat” effect. This was abnormal branching of the formed
filaments. Several of the filaments had a range of branching issues such as too many filaments
formed at the cell body and filaments growing from abnormal locations on an existing filament.
These abnormalities represented around 10% of filaments visualized at six hours after exposure.
The formation of a polarized actin patch is a key step in the proper formation of filaments. This
finding adds more support to the idea that occidiofungin disrupts the normal cellular actin
dynamics as proper filament formation to a polarized location requires actin and actin associated
proteins. The final abnormality identified was a profound reduction in the length of all filaments
formed with occidiofungin exposure. Untreated cells formed filaments that were around 100
micrometers in length by six hours after switching. The average length of filaments in the sublethal dosing group were ~18-19 micrometers which is a close to a 3-fold reduction in the length
of the filaments. This data suggests that while hyphae initiation may be recovered, the normal
growth of the resulting filament is severely impacted. This collection of data on sub-lethal dosing
points to irreversible damage that is done to normal filament formation when exposed to lower
concentrations of occidiofungin. When looking for treatment options for a pathogen whose
virulence is dependent on this morphology, occidiofungin may represent a promising option. If
treatment of sublethal dosing of occidiofungin creates damage to filaments but allows for the
survival and function of the yeast form, occidiofungin may reduce the damage done to the
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beneficial flora. This could reduce the amount of side effects seen with chronic antifungal
treatments that many patients must endure. More experiments into the nature of these defects,
whether C. albicans with these morphological defects have altered virulence, and morphological
effects of occidiofungin when used at even lower doses are called for to better explore this data.
The combined findings of this study have shown that occidiofungin is effective as an
antifungal compound against C. albicans cells that are undergoing morphological switching.
This antifungal activity results in the death of cells and the inhibition of surviving cells to switch
into the morphology that is considered virulent. This is likely mediated through its impact on
altering the organization of actin in these cells, possibly generating an inhibition or delay in
switching events that alter cell morphology. When these findings are combined with previous
work showing acceptable toxicity in mouse models, tolerance to low pH (important for oral
applications), and a broad range of fungal species effected, the potential applications for
occidiofungin could be numerous (Ellis et al., 2012; Tan et al., 2012).
There are a number of potential therapeutic uses for an antifungal compound with the
properties exhibited by occidiofungin. For example,
1. When applied to the site of dental implants a reduction in post implant candidiasis may
result.
2. Use as a pretreatment for IV lines susceptible to contamination by fungal colonization
might lower hospital acquired fungal infections.
3. Inoculation of plants with the bacteria that naturally produces occidiofungin could reduce
crop loss from fungal pathogens without the need for more potentially toxic pesticides.
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4. Treatment of difficult fungal diseases in domestic animals such as blastomycosis. A
potentially fatal fungal disease where the current treatments can have harsh and even fatal
side effects, could have improved outcomes with occidiofungin.
Continued research into occidiofungin is necessary to discover just how many of these
applications, if any, are viable. To this end, work must continue to determine the effects
occidiofungin has on cells post switching. The structural changes in actin organization in cells
treated with a sublethal dose of occidiofungin, and the impact of occidiofungin on biofilm
formation remain to be determined. These and many more questions must be asked to achieve a
true understanding of how occidiofungin will fit into its role as a future antifungal agent. We
believe that the findings in this study warrant the continued pursuit of research endeavors to
answer all of these questions.

.
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